Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Review

Design and in Vitro Neuroprotective Evaluation of Pyrimidine-Based Compounds for Alzheimer’s Therapy

V. Sharma G. Rani S. Rai A. Yasmeen Mohit Kumar O. Navneetha Sushil Kumar Gulia R. Solanki P. Geetha
· 0 citations · 111 references

TL;DR

This review highlights the pyrimidine scaffold as a privileged structure in medicinal chemistry for the development of neuroprotective agents, and details the evolution from single-target to multi-target design, focusing on hybrid molecules and metal.

Semantic Scholar
View source

Similar papers

Review Sep 2026

Beyond the Single-Target Approach: Polypharmacology and Multi-Target Therapeutics in Alzheimer's Disease.

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-beta aggregation, tau pathology, oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic degeneration. The limited clinical success of traditional single-target therapeutic approaches has highlighted th...

Renu Yadav, Jyoti Sinha, Km Deeksha · 0 citations
Review Sep 2026

Rivastigmine-centered molecular hybridization strategies for multi-targeted intervention in Alzheimer's disease: Advances (2020-2026).

This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment.

Nitin Kumar, V. Kushwaha, Gourav Singh et al. · 0 citations
Open access Sep 2026

Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease.

Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder, where disease-modifying therapy (DMT) represents a major unmet clinical need. Advances in the understanding of underlying pathogenesis reveal the potential therapeutic value of inhibitors targeting leucine-rich repeat kinase 2 (LRRK2...

Wen-Qing Xu, Tian-Qiang Liu, Xin-Yuan Miao et al. · 0 citations
Oct 2026

Discovery of a BBB-Penetrant Lanosterol Derivative as an Aβ Aggregation Inhibitor for Alzheimer’s Disease

The abnormal aggregation of amyloid-beta (Aβ) peptides is a core driver of Alzheimer’s disease (AD). Developing central nervous system (CNS)-penetrant small-molecule Aβ inhibitors offers a complementary strategy to overcome the high costs and severe side effects of antibodies. Lanosterol has demonstrated excellent po...

Bai-Chen Xiong, Teng-Fei Zhen, Xin-Hai Wang et al. · 0 citations
Review Open access Aug 2026

Xanthones and Their Nitrogen and Sulfur Analogs in Alzheimer’s Disease: Recent Progress Toward Multifunctional Therapeutics

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder and the leading cause of dementia among the elderly worldwide. In medicinal chemistry and drug discovery, heterocycles are widely recognized as privileged scaffolds due to their structural versatility and biological relevance. In the context of AD,...

Daniela Malafaia, Lúcia Melo, Artur M. S. Silva et al. · 0 citations
Open access Sep 2026

Structural optimization of donepezil-like hybrids toward an improved multi-target and ADME-related profile.

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving mainly cholinergic dysfunction, protein misfolding, and metal dyshomeostasis. Considering the complexity of the pathology, multi-target approaches represent a valuable alternative to current approved mono-target treatments. In this study,...

Marco Paparella, R. Leuci, Marco Cerini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.